Consensus Y-mAbs Therapeutics, Inc.

Equities

YMAB

US9842411095

Real-time Estimate Cboe BZX Other stock markets 19:11:05 29/04/2024 BST			5-day change	1st Jan Change
15.28 ^USD	+3.84%		+0.79%	+124.05%

03-14	Y-mAbs Therapeutics Chief Financial Officer Bo Kruse to Resign	MT
03-14	Y-mAbs Therapeutics, Inc. Announces Resignation of Bo Kruse as Executive Vice President, Secretary and Treasurer, Effective July 31, 2024	CI

Evolution of the average Target Price on Y-mAbs Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

2580c6ac78505a57b74.csodBl_gmfDQgEgkvzmX7KX989yAa4unf4pNw0AD9-g.QZ15ZQrQyJG_0BFU6wnGq_GfnIq1UsThPMgJ8wpJm7oGpVswCbTplaTZAQ~571ef5d8ee21b62ecff66615492133f6

Analyst Recommendations on Y-mAbs Therapeutics, Inc.

HC Wainwright Adjusts Price Target on Y-mAbs Therapeutics to $22 From $21, Keeps Buy Rating	03-06	MT
Canaccord Genuity Raises Price Target on Y-mAbs Therapeutics to $26 From $22, Maintains Buy Rating	03-04	MT
BMO Capital Adjusts Y-mAbs Therapeutics Price Target to $26 From $16, Maintains Outperform Rating	03-04	MT
Wedbush Raises Y-mAbs Therapeutics' PT to $23 From $18 After Higher-Than-Expected Q4 2023 Danyelza Net Product Revenue, Maintains Outperform Rating	03-04	MT
HC Wainwright Adjusts Y-mAbs Therapeutics Price Target to $21 From $11, Maintains Buy Rating	02-20	MT
Wedbush Raises Price Target on Y-mAbs Therapeutics to $18 From $12 After Plans for Phase 1 Cancer Drug Study, Keeps Outperform Rating	02-12	MT
Kempen Upgrades Y-mAbs Therapeutics to Buy From Neutral, Price Target is $10	12-22	MT
JPMorgan Adjusts Y-mAbs Therapeutics Price Target to $7 From $8, Maintains Underweight Rating	22/08/23	MT
Morgan Stanley Adjusts Price Target on Y-mAbs Therapeutics to $5 From $7, Maintains Underweight Rating	14/08/23	MT
Wedbush Trims Y-mAbs Therapeutics' Price Target to $12 From $13, Keeps Outperform Rating	11/08/23	MT
Canaccord Genuity Adjusts Y-mAbs Therapeutics' Price Target to $22 From $21, Keeps Buy Rating	25/07/23	MT
Morgan Stanley Adjusts Price Target on Y-mAbs Therapeutics to $7 From $4, Maintains Underweight Rating	10/05/23	MT
BMO Capital Raises Y-mAbs Therapeutics' Price Target to $15 From $13, Maintains Outperform Rating	10/05/23	MT
Wedbush Upgrades Y-mAbs Therapeutics to Outperform From Neutral, Notes Danyelza Return to Growth Trajectory; Raises PT to $13 From $5	10/05/23	MT
Canaccord Genuity Adjusts Y-mAbs Therapeutics Price Target to $21 From $18, Maintains Buy Rating	09/05/23	MT
HC Wainwright Lowers Price Target on Y-mAbs Therapeutics to $11 From $19, Maintains Buy Rating	04/04/23	MT
Guggenheim Downgrades Y-mAbs Therapeutics to Neutral From Buy	03/04/23	MT
Canaccord Genuity Adjusts Price Target on Y-mAbs Therapeutics to $18 From $20, Maintains Buy Rating	31/03/23	MT
BMO Capital Adjusts Price Target on Y-mAbs Therapeutics to $13 From $12, Maintains Outperform Rating	30/01/23	MT
Morgan Stanley Downgrades Y-mAbs Therapeutics to Underweight From Equal Weight	27/01/23	MT
Cowen Downgrades Y-mAbs Therapeutics to Market Perform From Outperform	05/01/23	MT
Wedbush Lifts Y-mAbs Therapeutics' PT to $5 From $4 After Announced Plan to Reduce Operating Expenses, Keeps Neutral Rating	05/01/23	MT
Wedbush Lowers Y-mAbs Therapeutics' Price Target to $4 From $6, Keeps Neutral Rating	09/11/22	MT
BMO Capital Adjusts Price Target for Y-mAbs Therapeutics to $12 From $29, Keeps Outperform Rating	01/11/22	MT
Kempen Downgrades Y-mAbs Therapeutics to Neutral From Buy, Lowers Price Target to $6 From $20	31/10/22	MT